A recent study reported that I-BET151 inhibited RANKL-induced osteoclastogenesis and bone loss in post-ovariectomy osteoporosis, inflammatory arthritis, and TNF-induced osteolysis mouse models by targetting MYC-NFAT axis [41]. The gene discussed is MYC; the disease is primary osteolysis.